


RealRate

PHARMACEUTICAL 2019

ABBOTT LABORATORIES Rank 31 of 363









RealRate

PHARMACEUTICAL 2019



ABBOTT LABORATORIES Rank 31 of 363

The relative strengths and weaknesses of ABBOTT LABORATORIES are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ABBOTT LABORATORIES compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 87% points. The greatest weakness of ABBOTT LABORATORIES is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 267%, being 230% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	14,632,000
Cost of Goods Sold	12,706,000
Intangible Assets	42,196,000
Liabilities, Current	9,012,000
Liabilities, Non-Current	0
Other Assets	2,782,000
Other Compr. Net Income	-1,192,000
Other Expenses	3,543,000
Other Liabilities	0
Other Net Income	83,000
Other Revenues	30,578,000
Property and Equipment	7,563,000
Research and Development	2,300,000
Selling, General and Administrative Expense	9,744,000

Output Variable	Value in 1000 USD
Assets	67,173,000
Liabilities	9,012,000
Expenses	28,293,000
Revenues	30,578,000
Stockholders Equity	58,161,000
Net Income	2,368,000
Comprehensive Net Income	1,772,000
Economic Capital Ratio	267%

